AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
iotalamic acid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| iodine-containing contrast media | 1469 | 2276-90-6 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A contrast medium in diagnostic radiology with properties similar to those of diatrizoic acid. It is used primarily as its sodium and meglumine (IOTHALAMATE MEGLUMINE) salts.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| Vd (Volume of distribution) | 0.17 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 2.40 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.98 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 1.30 hours | Lombardo F, Berellini G, Obach RS |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AURKC,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK4,CDK5,CDK9,DDR1,DYRK1B,DYRK3,EGFR,EIF2AK3,EPHB4,ERBB2,FLT3,FLT4,GRK2,GRK3,GSK3B,IKBKB,ITK,JAK1,JAK2,KDR,KIT,MAP2K6,MAP3K14,MAP3K2,MAP3K21,MAP3K3,MAP3K7,MAP4K1,MAPK1,MAPK10,MAPK12,MAPK7,MAPK8,MAPK9,MAPKAPK2,MAPKAPK5,MARK4,MELK,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM1,PIM2,PIM3,PLK1,PRKCD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 | 77 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,ALK,AURKA,AURKB,AURKC,AXL,BRAF,CAMK2A,CAMK2B,CAMK2D,CDK1,CDK16,CDK2,CDK3,CDK4,CDK6,CDK7,CDK9,CLK2,CLK4,DDR1,DYRK1A,DYRK1B,DYRK3,EIF2AK3,EPHB4,ERBB2,FGFR1,FLT3,FLT4,GRK2,GSK3A,GSK3B,HIPK2,IRAK1,JAK1,JAK2,MAP2K3,MAP2K4,MAP2K6,MAP3K11,MAP3K14,MAP3K2,MAP3K21,MAP3K7,MAP4K1,MAPK1,MAPK12,MAPK7,MAPK8,MARK4,MELK,MET,MTOR,PDK4,PIK3CA,PIK3CB,PIK3CD,PIK3CG,PIM3,PRKAA1,PRKCZ,PRKDC,SGK1,SIK2,SIK3,STK10,STK33,SYK,TEK,TGFBR1,TNIK,TTK,UHMK1,ULK1,ULK2,ZAP70 | 78 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Sept. 30, 1963 | FDA | MALLINCKRODT |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | V08AA04 | VARIOUS CONTRAST MEDIA X-RAY CONTRAST MEDIA, IODINATED Watersoluble, nephrotropic, high osmolar X-ray contrast media |
| FDA MoA | N0000010258 | X-Ray Contrast Activity |
| MeSH PA | D003287 | Contrast Media |
| FDA EPC | N0000180185 | Radiographic Contrast Agent |
| CHEBI has role | CHEBI:35703 | Xenobiotic |
| CHEBI has role | CHEBI:37338 | contrast media |
| CHEBI has role | CHEBI:78298 | environmental contaminants |
Related Drugs by ATC class:
V08AA Watersoluble, nephrotropic, high osmolar X-ray contrast media 9 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 3.1 | acidic |
| pKa2 | 13.94 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
None
External reference:
| ID | Source |
|---|---|
| N0000166657 | NUI |
| D01258 | KEGG_DRUG |
| 4018169 | VANDF |
| 4018170 | VANDF |
| CHEBI:31713 | CHEBI |
| CHEMBL1201300 | ChEMBL_ID |
| DB09133 | DRUGBANK_ID |
| DB00271 | DRUGBANK_ID |
| 1546451 | RXNORM |
| 4908 | MMSL |
| 000669 | NDDF |
| 002344 | NDDF |
| 004528 | NDDF |
| 004956 | NDDF |
| 395982009 | SNOMEDCT_US |
| 783807009 | SNOMEDCT_US |
| C0022034 | UMLSCUI |
| D007483 | MESH_DESCRIPTOR_UI |
| CHEMBL1201125 | ChEMBL_ID |
| CHEMBL1097620 | ChEMBL_ID |
| 3737 | PUBCHEM_CID |
| 13087-53-1 | SECONDARY_CAS_RN |
| 1225-20-3 | SECONDARY_CAS_RN |
| 1371 | INN_ID |
| D007482 | MESH_DESCRIPTOR_UI |
| 16CHD79MIX | UNII |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Cysto-Conray II | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0019-0862 | INJECTION | 172 mg | URETERAL | NDA | 19 sections |
| Conray | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0019-0953 | INJECTION | 600 mg | INTRAVASCULAR | NDA | 20 sections |